Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Non-Current Deffered Revenue: 2021-2024

Historic Non-Current Deffered Revenue for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $31.4 million.

  • ProQR Therapeutics N.V's Non-Current Deffered Revenue fell 33.83% to $31.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.4 million, marking a year-over-year decrease of 33.83%. This contributed to the annual value of $31.4 million for FY2024, which is 34.18% down from last year.
  • As of FY2024, ProQR Therapeutics N.V's Non-Current Deffered Revenue stood at $31.4 million, which was down 34.18% from $47.8 million recorded in FY2023.
  • In the past 5 years, ProQR Therapeutics N.V's Non-Current Deffered Revenue registered a high of $66.9 million during FY2022, and its lowest value of $17.4 million during FY2021.
  • Its 3-year average for Non-Current Deffered Revenue is $48.7 million, with a median of $47.8 million in 2023.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 284.89% in 2022, then tumbled by 34.18% in 2024.
  • ProQR Therapeutics N.V's Non-Current Deffered Revenue (Yearly) stood at $17.4 million in 2021, then spiked by 284.89% to $66.9 million in 2022, then fell by 28.58% to $47.8 million in 2023, then tumbled by 34.18% to $31.4 million in 2024.